Request Additional Trial Information
Full Trial Details: ClinicalTrials.gov
Condition: Lung Cancer
Study Type: Interventional
Study Start Date: 04/03/2019
Study Completion Date: 06/2022
This is a Phase 1/1b, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB928 in combination with carboplatin/pemetrexed with or without pembrolizumab and AB122 monotherapy in participants with non-squamous Non-Small Cell Lung Cancer (NSCLC).